8 results about "Catecholaminergic" patented technology

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present application relates to the field of clinical laboratory medicine technology, in particular to a neuroblastoma and catecholamine-related tumor diagnosis kit and its application. The kit contains key components for detecting high vanillylmandelic acid and vanillylmandelic acid in urine, including isotope internal standard, specific chromatographic column, optimized mobile phase and sample pretreatment material. The detection method using the kit optimizes the collection, preservation and pretreatment process of instant urine samples, and combines the liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis conditions designed for low concentration and complex matrix samples to realize the rapid and accurate quantification of trace HVA and VMA in urine. It overcomes the shortcomings of traditional 24-hour urine detection method such as large trauma, long cycle and poor accuracy, and provides an efficient and reliable solution for non-invasive, early diagnosis and postoperative efficacy monitoring of neuroblastoma and other catecholamine-related tumors, which has important clinical application value.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The application discloses a method for preparing a mesoporous hollow nanoscale spherical structure adsorbent based on emulsion and micelle assembly and application of the adsorbent in uranium extraction. The mesoporous hollow nanoscale spherical structure material is combined with an amidoxime group, and a green and efficient uranium extraction adsorbent is prepared through a soft template method, self-polymerization of dopamine and amidoximation reaction. First, a nonionic surfactant, dopamine hydrochloride and an expanding agent 1,3,5-trimethylbenzene are used to form an emulsion / micelle system, ammonia is added after stirring to initiate the oxidative self-polymerization reaction of dopamine, and a mesoporous hollow nanoscale spherical catecholamine polymer MHS is prepared; then, a functional monomer 2-amino-3,5-divinylbenzonitrile is grafted to the MHS under the initiation of AIBN, and a cyan-amino bifunctionalized nanosphere CN-NH2-MHS is obtained; finally, the CN-NH2-MHS is chemically modified by hydroxylamine hydrochloride, the cyan group is converted into an amidoxime AO group, and thus an amidoxime-amino synergistically functionalized high-stability mesoporous hollow nanoscale spherical structure adsorbent AO-NH2-MHS is prepared.

The invention relates to methods for improving treatment outcomes in patients undergoing ultrafiltration. Ultrafiltration during hemodialysis or fluid removal can induce sympathetic nervous system activation, hypovolemia, catecholamine surge, and widespread microvascular ischemia, leading to cardiac stunning, dialysis intolerance, and organ injury. Disclosed herein are methods of administering a therapeutically effective amount of one or more receptor agonists of the renin-angiotensin system (RAS), including angiotensin II, angiotensin III, angiotensin IV, angiotensin 1-7, and / or prorenin receptor (PRR) agonists, to maintain capillary perfusion and prevent ischemia. The methods reduce risk or incidence of catecholamine surge, intradialytic hypotension, cardiac dysfunction, and muscle cramps, and also prevent or minimize systemic ischemic injury to the brain, heart, kidneys, liver, and skeletal muscle. By preserving systemic microvascular blood flow, the disclosed methods mitigate or prevent dialysis-associated heart disease as well as neurocognitive impairment, including white matter injury, memory decline, and executive dysfunction. These approaches enable improved hemodynamic stability, achieving ultrafiltration targets without the need to adjust treatment goals, reducing the necessity for fluid bolus administration, aiding in reaching dry weight, achievement of dry weight goals, minimizing the occurrence and severity of skeletal muscle cramps, and reduced long-term cardiovascular and neurological complications in patients receiving ultrafiltration therapy.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I), as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.